Prevalence of hot flushes and night sweats around the world: a systematic review

Freeman, Ellen W.; Sherif, Katherine

doi:10.1080/13697130601181486

Cited by 344 publications

(170 citation statements)

References 86 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…During the transition, a number of signs and symptoms may occur, including, vasomotor symptoms (hot flashes, palpitations), psychological symptoms (mood changes, depression, irritability, anxiety, sleep disturbances), cognitive symptoms memory problems, concentration) and, atrophic effects (atrophic vaginitis, bladder irritability) [1][2][3][4]. Women also report symptoms including night sweats, headaches, fatigue, decreased libido, severe itchiness, and back and muscle pains [5].…”

Section: Introductionmentioning

confidence: 99%

“…Women also report symptoms including night sweats, headaches, fatigue, decreased libido, severe itchiness, and back and muscle pains [5]. Such symptoms can significantly disrupt a woman's daily activities and overall quality of life [1][2][3][4]. Further, during menopause and aging, with changing hormone levels, women are at an increased change of chronic conditions such as, cancer, type-2 diabetes, autoimmunity, osteoporosis and cardiovascular diseases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

To exercise, or, not to exercise, during menopause and beyond

Stojanovska¹,

Apostolopoulos²,

Polman³

et al. 2014

Maturitas

104

View full text Add to dashboard Cite

Menopausal symptoms in women can be severe and disruptive to overall quality of life. Hormone replacement therapy, is known to be effective in ameliorating symptoms, however, reporting of side effects has resulted in alternative treatment options. Exercise has been assessed as an alternative treatment option for alleviating menopausal symptoms, including, psychological, vasomotor, somatic and sexual symptoms. Here we report the effects of physical activity and exercise on menopause symptoms in menopausal women.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

To exercise, or, not to exercise, during menopause and beyond

Stojanovska¹,

Apostolopoulos²,

Polman³

et al. 2014

Maturitas

104

View full text Add to dashboard Cite

show abstract

“…1 For some women, they can lead to significant physical distress and functional impairment requiring medical intervention. 2 Hot flashes are described as spontaneous sensations of warmth affecting the face, neck and upper chest, and are often associated with palpitation, sweating and anxiety.…”

Section: Introductionmentioning

confidence: 99%

SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials

et al. 2013

View full text Add to dashboard Cite

BACKGROUND: Hot flashes are the most commonly reported vasomotor symptom during the peri-and early post-menopausal period. OBJECTIVES: To systematically review, appraise and summarize the evidence of the impact of different SSRIs on peri-menopausal hot flashes in healthy women in randomized, controlled trials. METHODS: A comprehensive literature search was conducted of MEDLINE™, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus through March 2013. Two independent reviewers selected studies and extracted data. Random effects meta-analysis was used to pool outcomes across studies, and Bayesian mixed treatment methods were used to rank SSRIs in terms of effectiveness. RESULTS: We included a total of 11 randomized controlled trials with good methodological quality enrolling 2,069 menopausal and post-menopausal women (follow-up 1-9 months, mean age 36-76 years, mean time since menopause 2.3-6.6 years). Compared with placebo, SSRIs were associated with a statistically significant decrease in hot flash frequency (difference in means −0.93; 95 % CI −1.46 to −0.37; I 2 = 21 %) and severity assessed by various scales (standardized difference in means −0.34; 95 % CI −0.59 to −0.10; I 2 = 47 %). Adverse events did not differ from placebo. Mixed treatment comparison analysis demonstrated the superiority of escitalopram compared to other SSRIs in terms of efficacy. CONCLUSION: SSRI use is associated with modest improvement in the severity and frequency of hot flashes but can also be associated with the typical profile of SSRI adverse effects.

show abstract

“…It can be explained because one-half of the women in our study were at the menopausal transition or early postmenopause, where menopausal symptoms are more prevalent (25), but other factors, i.e., ethnicity, health status, etc., cannot be ruled out (26).…”

Section: Discussionmentioning

confidence: 98%

Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: A randomized, double‐blind, controlled trial

Cravioto¹,

Durand-Carbajal²,

Jiménez-Santana³

et al. 2011

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To define the effects of continuous sequential estrogen plus progestin therapy on menopausal symptoms in women with systemic lupus erythematosus (SLE).Methods. We performed a randomized, double-blind, 24-month clinical trial involving 106 women with SLE who were in the menopausal transition or early or late postmenopause. Patients received continuous sequential estrogen plus progestin (n ‫؍‬ 52) or placebo (n ‫؍‬ 54). Menopausal symptoms were assessed using the Greene Climacteric Scale at 0, 1, 2, 3, 6, 9, 12, 15, 18, 21, and 24 months. A new factor analysis of the scale reduced 21 items to 5 factors. The primary outcome was improvement of menopausal symptoms throughout the followup period. Results were analyzed by the intent-to-treat principle. Results. At baseline, demographic and disease characteristics were similar in both groups. Fifteen of 21 menopausal symptoms had a prevalence of >50%, with a similar distribution between groups. Vasomotor factor scores decreased over time in both groups (P ‫؍‬ 0.002), but in the estrogen plus progestin group the reduction was more pronounced than in the placebo group (1.5-2.0 versus 0.35-0.8 points on a scale of 0 -6; P ‫؍‬ 0.03). Maximum effects were observed among the most symptomatic women. Psychological, subjective-somatic, and organic-somatic factors scores also improved along time (P < 0.001), but the treatment and placebo arms improved to a similar degree. Thromboses occurred in 3 patients receiving estrogen plus progestin and in 1 patient receiving placebo. Conclusion. Menopausal symptoms are highly prevalent in peri-and postmenopausal lupus patients. Estrogen plus progestin improved vasomotor symptoms at a clinically significant level, but not other menopausal symptoms. Given the thrombotic risks of menopausal hormone therapy, this should be used only in women with significant vasomotor symptoms.

show abstract

Prevalence of hot flushes and night sweats around the world: a systematic review

Abstract: Caregivers should recognize that variations exist and ask patients specific questions about symptoms and their impact on usual functioning.

Cited by 344 publications

References 86 publications

To exercise, or, not to exercise, during menopause and beyond

To exercise, or, not to exercise, during menopause and beyond

SSRIs for Hot Flashes: A Systematic Review and Meta-Analysis of Randomized Trials

Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: A randomized, double‐blind, controlled trial

Contact Info

Product

Resources

About